Table 1.

Clinicopathological patient characteristics.

Characteristic	Training set	Validation set
	(N = 944)	(N = 236)
Age (years)
≤48	483 (51.2%)	117 (49.6%)
>48	461 (48.8%)	119 (50.4%)
Histological type
Invasive ductal carcinoma	822 (87.1%)	182 (77.1%)
Others	122 (12.9%)	54 (22.9%)
Tumor grade
1	27 (2.9%)	6 (2.5%)
2	650 (68.9%)	168 (71.2%)
3	191 (20.2%)	47 (19.9%)
Unknown	76 (8.0%)	15 (6.4%)
T stage
0	2 (0.2%)	0 (0.0%)
1	313 (33.2%)	101 (42.8%)
2	552 (58.5%)	109 (46.2%)
3	43 (4.6%)	10 (4.2%)
4	34 (3.6%)	16 (6.8%)
N stage
0	482 (51.1%)	124 (52.5%)
1	260 (27.5%)	63 (26.7%)
2	121 (12.8%)	28 (11.9%)
3	81 (8.6%)	21 (8.9%)
Clinical stage
1	209 (22.1%)	67 (28.4%)
2	513 (54.4%)	109 (46.2%)
3	222 (23.5%)	60 (25.4%)
Molecular subtype
Luminal A	205 (21.7%)	61 (25.8%)
Luminal B/HER2-	354 (37.5%)	65 (27.6%)
Luminal B/HER2+	119 (12.6%)	31 (13.1%)
HER2 Enriched	125 (13.2%)	42 (17.8%)
Triple Negative	141 (14.9%)	37 (15.7%)
ER
Negative	281 (29.8%)	88 (37.3%)
Positive	663 (70.2%)	148 (62.7%)
PR
Negative	359 (38.0%)	92 (39.0%)
Positive	585 (62.0%)	144 (61.0%)
HER2
Negative	659 (69.8%)	159 (67.4%)
Positive	285 (30.2%)	77 (32.6%)
Ki67
Negative	313 (33.2%)	90 (38.1%)
Positive	631 (66.8%)	146 (61.9%)
Adjuvant chemotherapy
Yes	787 (83.4%)	174 (73.4%)
No	157 (16.6%)	62 (26.3%)
Endocrine therapy
Yes	661 (70.0%)	146 (61.8%)
No	281 (29.8%)	90 (38.2%)
Unknow	2 (0.2%)
Radiotherapy
Yes	246 (26.1%)	76 (32.3%)
No	698 (73.9%)	160 (67.8%)
Target therapy
Yes	61 (6.5%)	23 (9.7%)
No	883 (93.5%)	213 (90.3%)
SIS-group
<1	649 (68.8%)	151 (63.9%)
≥1	295 (31.3%)	85 (36.1%)

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; SIS, Systemic inflammation score.